- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02697552
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
Study Overview
Detailed Description
Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally. Patients must be hospitalized as per guidance of the treating investigator throughout Cycle 1. Patients will receive HBI 8000 twice weekly (BIW) (after breakfast), in 28 day treatment cycles.
Patients will be enrolled in cohorts of 3 patients. The first cohort of 3 patients will receive 30 mg BIW. Decisions regarding cohort escalation will be based upon the clinical experience in Cycle 1 (first 28 days) only. For a given cohort, if 1 patient enrolled in the cohort experiences a dose limiting toxicity (DLT) within 28 days of the first dose, the cohort will be expanded to 6 patients.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Aichi, Japan
- Nagoya City University Hospital
-
Fukuoka, Japan
- Fukuoka University Hospital
-
Fukuoka, Japan
- NHO Kyushu Cancer Center
-
Kagoshima, Japan
- Kagoshima University Medical and Dental Hospital
-
Kanagawa, Japan
- Tokai University Hospital
-
Kumamoto, Japan
- Nho Kumamoto Medical Center
-
Nagasaki, Japan
- NHO Nagasaki Medical Center
-
Tokyo, Japan
- National Cancer Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically diagnosed non Hodgkin's lymphoma patients for whom no other standard therapy is available
- Male or female, aged 20 years or over at time of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy, per the investigator, of more than 3 months at time of signing informed consent
- Patients for whom at least 1 measurable lesion is confirmed in the lesion assessment before the start of study drug administration
Patients must have recovered to Grade 1 or less (Common Terminology Criteria for Adverse Events [CTCAE], Version 4.03) from all toxicity associated with previous chemotherapy, antibody, or radiotherapy. (Exception: patients may enter with continuing alopecia regardless of CTCAE grade.) The following intervals between ending of another treatment and starting of HBI-8000 must elapse:
- Chemotherapy: 4 weeks
- Nitrosourea: 6 weeks
- Radiotherapy: 4 weeks
- Major surgery: 4 weeks
- Immunomodulatory drugs: 4 weeks
- Any antibody agent: 12 weeks (84 days)
- Autologous stem cell transplantation (ASCT): 12 weeks (84 days)
- Patients must agree not to consume grapefruit, grapefruit juices, Seville oranges, St.John's wort, or any products containing Seville oranges, grapefruit, or St. John's wort during their participation on the study
- Patients who signed the informed consent form and are capable of giving informed consent in accordance with the policies of the Institutional Review Board (IRB)
- Patients must be willing to be hospitalized as per guidance of the treating investigator throughout Cycle 1
Exclusion Criteria:
- Patients with current, previous, or clinically suspected invasion of the central nervous system (CNS)
- Organ transplant recipients
- Allogeneic stem cell transplant recipients
- Previous extensive radiotherapy involving ≥30% of hematopoietic bone marrow, excluding patients who have had total body irradiation as part of a conditioning regimen for ASCT
- Patients with an electrocardiogram (ECG) finding at screening of QT interval corrected for heart rate using Fridericia's method (QTcF) prolongation >450 ms in male patients and >470 ms in female patients, ventricular tachycardia, ventricular fibrillation, second- or third-degree heart block, unstable angina, coronary angioplasty or stenting, myocardial infarction, chronic congestive heart failure (New York Heart Association Class III or IV) within 6 months of starting the study drug, any cardiomyopathy, or long QT syndrome
Any condition including the presence of laboratory abnormalities, which, as judged by the investigator, places the patient at unacceptable risk if he/she were to participate in the study. Examples of such medical conditions are, but are not limited to, as follows:
• Uncontrolled diabetes mellitus (e.g., glycosylated hemoglobin [HbA1c] >8%), as judged by the investigator
Patients who have had any of the following abnormal measurements at screening performed within 2 weeks (14 days) prior to the start of study drug administration:
- Hemoglobin: <8 g/dL
- Neutrophil count: <1,200/µL
- Platelet count: <75,000/µL
- Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT): >3 x the upper limit of normal (ULN)
- Bilirubin level: >1.5 x ULN
- Creatinine clearance: <50 mL/min via Cockcroft-Gault formula ; proteinuria > Grade 2
- Plasma troponin I (or troponin T): >ULN
- Prothrombin time or activated partial thromboplastin time: >1.25 x ULN
- Potassium, corrected calcium , or magnesium levels outside normal limits
- Any cardiac arrhythmia requiring anti-arrhythmic medication
- Patients with a history of seizures
- Patients with known hypersensitivity to histone deacetylase (HDAC) inhibitors or any of the components of the HBI-8000 tablets
Patients with a history or complication of malignant tumors, unless the patients have been free of the disease for 5 years or longer, except the following, if successfully treated, in which case they are not excluded:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin
- Cervical carcinoma in situ
- Carcinoma in situ of the breast
- An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
- Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
- Patients with uncontrolled inter-current infection
- Patients with active clinically significant bleeding or recently occurred thrombotic diseases, including patients who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic prophylaxis
Women who are pregnant, women who are not willing to stop breastfeeding during study period and for 10 days after the last dose of study drug, women of child bearing potential, or men with a sexual partner of child bearing potential who are not willing to use double-barrier method during study period and at least 3 months (for men) or at least 1 month (for women) after the last dose of study drug. Double-barrier method is defined as a combination of 2 effective contraceptive methods, such as condom or condom containing spermicide in combination with a diaphragm, oral contraceptive, or intrauterine device.
Note: Female subjects will be considered to be a woman of childbearing potential unless having undergone permanent contraception or postmenopausal. Postmenopausal is defined as at least 12 months without menses with no other medical reasons (i.e., chemical menopause because of treatment with anti-malignant tumor agents).
- Seropositivity for the human immunodeficiency virus (HIV) antibody
- Hepatitis B surface antigen-positive, or hepatitis C virus antibody positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen negative, a hepatitis B virus deoxyribonucleic acid (DNA) test [real-time polymerase chain reaction (PCR]) measurement] should be performed and if positive, the patient should be excluded
- Patients who were in other experimental clinical studies with investigational agents within 30 days before the start of study drug administration (12 weeks for any investigational antibody therapy or investigational ASCT), or in current clinical studies with investigational agents
- Patients with a history of drug abuse or long-term excessive alcohol consumption which could affect study result assessment
- Patients considered by the investigator to be unsuitable for the study because of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study, or because of any condition that confounds the ability to interpret data from the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HBI-8000
HBI-8000 at the assigned dose twice weekly.
|
Oral doses of 30mg, 40mg, 50mg twice weekly [BIW].
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of HBI-8000 in adult Japanese patients with non Hodgkin's lymphoma (NHL) for whom no other standard therapy is suitable based on the frequency of dose-limiting toxicities (DLTs) which occur within 28 days.
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter: area under the plasma concentration-time curve (AUC) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.
Time Frame: 28 days
|
Plasma concentration of HBI-8000 will be measured following single dose (Days 1-4) and multiple dose (Days 25-28) administration
|
28 days
|
Pharmacokinetic parameter: maximum observed plasma concentration (Cmax) measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.
Time Frame: 28 days
|
Plasma concentration of HBI-8000 will be measured following single dose (Days 1-4) and multiple dose (Days 25-28) administration
|
28 days
|
Pharmacokinetic parameter: time of maximum observed plasma concentration (Tmax) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.
Time Frame: 28 days
|
Plasma concentration of HBI-8000 will be measured following single dose (Days 1-4) and multiple dose (Days 25-28) administration
|
28 days
|
Pharmacokinetic parameter: apparent terminal half-life (T1/2) at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.
Time Frame: 28 days
|
Plasma concentration of HBI-8000 will be measured following single dose (Days 1-4) and multiple dose (Days 25-28) administration
|
28 days
|
Anti-tumor activity of HBI-8000 by overall response status based on Cheson's response criteria for NHL and Japan Clinical Oncology Group (JCOG) response criteria for Adult T-Cell Lymphoma (ATL)
Time Frame: Through study completion, an average of 24 weeks.
|
Through study completion, an average of 24 weeks.
|
|
Safety of HBI-8000 in Japanese patients with NHL for whom no other standard therapy is suitable with incidence and severity of adverse events graded according to the NCI-CTCAE version 4.03
Time Frame: Through study completion, an average of 24 weeks.
|
Through study completion, an average of 24 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kensei Tobinai, MD, National Cancer Center Hospital Tokyo, Japan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBI-8000-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on HBI-8000
-
HUYABIO International, LLC.Quintiles, Inc.CompletedAdult T-Cell Lymphoma (ATL)Japan
-
HUYABIO International, LLC.Quintiles, Inc.CompletedPeripheral T-Cell Lymphoma (PTCL)Japan, Korea, Republic of
-
Shandong UniversityUnknownThrombocytopeniaChina
-
Great Novel Therapeutics Biotech & Medicals CorporationRecruitingRelapsed or Refractory Peripheral T-cell LymphomaTaiwan
-
oubaiUnknownDiffuse Large B-cell LymphomaChina
-
Yuankai ShiUnknownAdvanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
-
Great Novel Therapeutics Biotech & Medicals CorporationRecruiting
-
Tang-Du HospitalChipscreen Biosciences, Ltd.CompletedChronic HIV InfectionsChina
-
HUYABIO International, LLC.CompletedMelanoma | Renal Cell Carcinoma | Non-Small Cell Lung CancerUnited States
-
Yuankai ShiUnknownPeripheral T Cell Lymphoma